Return to homepagePandemic Pact

MetInCoV: SARS-CoV-2 N7-methyltransferase inhibitors: an unusual therapeutic target against Covid-19

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    ANR

  • Principal Investigator

    Françoise Debart

  • Research Location

    France

  • Lead Research Institution

    CNRS / Montperllier

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The MetInCoV project, coordinated by Françoise Debart (UMR 5247 - Institut des Biomolécules Max Mousseron (IBMM) - CNRS / Montperllier), offers a multidisciplinary approach combining molecular design, chemical synthesis and robust in vitro tests for the development of new nucleoside antivirals against a less explored molecular target: N7-MTase nsp14 from SARS-CoV-2. Indeed, the N7- and 2-O-methylations of the viral RNA cap are key events of viral infection because their inhibition could limit the synthesis of viral proteins and promote the elimination of the virus by stimulating the response. immune.